merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>Safer option than compounded drugs</answer>
<question_number>2</question_number>
<answer>Vials can be delivered right to patients' doors</answer>
<question_number>3</question_number>
<answer>Less oversight than traditionally approved medications</answer>
<question_number>4</question_number>
<answer>To regain customers getting compounded tirzepatide</answer>
<question_number>5</question_number>
<answer>FDA will have to review the supply before taking it off its shortage list</answer>
<question_number>6</question_number>
<answer>Transparent pricing</answer>
<question_number>7</question_number>
<answer>Unique risks for older patients</answer>
<question_number>8</question_number>
<answer>Safer option</answer>
<question_number>9</question_number>
<answer>FDA lists as "in shortage"</answer>
<question_number>10</question_number>
<answer>Lower pricing</answer>
